RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

  • Ph Gabriel Steg
  • Shamir R Mehta
  • J Wouter Jukema
  • Gregory Y.H. Lip
  • C Michael Gibson
  • Frantisek Kovar
  • Petr Kala
  • Alberto Garcia-Hernandez
  • Ronny W Renfurm
  • Christopher B Granger
  • RUBY-1 Investigators
  • Torp-Pedersen, Christian Tobias
To establish the safety, tolerability and most promising regimen of darexaban (YM150), a novel, oral, direct factor Xa inhibitor, for prevention of ischaemic events in acute coronary syndrome (ACS).
OriginalsprogEngelsk
TidsskriftEuropean Heart Journal (Online)
Vol/bind32
Udgave nummer20
Sider (fra-til)2541-54
Antal sider14
ISSN1522-9645
DOI
StatusUdgivet - okt. 2011

ID: 48592247